Editorial

You have full text access to this OnlineOpen article

Increased liver-related mortality to hepatitis C viremia defined on the 20th anniversary of its identification†‡

  1. Elizabeth Kenny-Walsh*

Article first published online: 29 MAY 2009

DOI: 10.1002/hep.23107

Issue

Hepatology

Hepatology

Volume 50, Issue 2, pages 349–351, August 2009

Additional Information

How to Cite

Kenny-Walsh, E. (2009), Increased liver-related mortality to hepatitis C viremia defined on the 20th anniversary of its identification. Hepatology, 50: 349–351. doi: 10.1002/hep.23107

Author Information

  1. Health Service Executive, Dublin, Ireland

*Health Service Executive, Cork, Ireland

  1. †

    See Article on Page 393

  2. ‡

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 29 JUL 2009
  2. Article first published online: 29 MAY 2009
  3. Accepted manuscript online: 29 MAY 2009 12:00AM EST

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (58K)

References

  • 1
    Kim WR. Global epidemiology and burden of hepatitis C. Microbes Infect 2002; 4: 1219–1225.
  • 2
    Global surveillance and control of hepatitis C. Report of a WHO consultation organised in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35–47.
  • 3
    Perz J, Farrington L, Pecoraro C, Hutin YJF, Armstrong GL. Estimated global prevalence of hepatitis C virus infection. Presented at the 42nd annual meeting of the Infectious Diseases Society of America; September 30-October 3, 2004; Boston, MA.
  • 4
    Armstrong G, Alter M, McQuillan G, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. HEPATOLOGY 2000; 31: 777–782.
    Direct Link:
  • 5
    Centers for Disease Control and Prevention. Viral Hepatitis website. http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/disease_burden2004.pdf. Accessed May 2009.
  • 6
    Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797–1801.
  • 7
    Tanaka Y, Kurbanov F, Mano S, Orito E, Vargas V, Esteban JI, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 2006; 130: 703–714.
  • 8
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRX, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–832.
  • 9
    European Association for the Study of the Liver International Consensus Conference on Hepatitis C. Consensus Statement. February 26–28, 1999; Paris, France. J Hepatol 1999; 30: 956–961.
  • 10
    Alter H, Conry-Cantalena C, Melpolder J. Hepatitis C in asymptomatic blood donors. HEPATOLOGY 1997; 26( Suppl 1): 29S–33S.
    Direct Link:
  • 11
    Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. HEPATOLOGY 2001; 33: 455–463.
    Direct Link:
  • 12
    Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450–456.
  • 13
    Vogt M, Lang T, Frösner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866–870.
  • 14
    Locasciulli A, Testa M, Pontisso P. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood 1997; 90: 4628–4633.
  • 15
    Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single source outbreak in Germany: a 20-year multicenter study. HEPATOLOGY 2000; 32: 91–96.
    Direct Link:
  • 16
    Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228–1233.
  • 17
    Alter M, Kruszon-Moran D, Nainan O, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556–562.
  • 18
    Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. HEPATOLOGY 2008; 47: 1058–1066.
    Direct Link:
  • 19
    Everhart J, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH, et al. Recurrent and new hepatitis C virus infection after liver transplantation. HEPATOLOGY 1999; 29: 1220–1226.
    Direct Link:
  • 20
    Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416–423.
  • 21
    Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. HEPATOLOGY 2001; 34: 809–816.
    Direct Link:
  • 22
    Seeff L. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36(5 Suppl 1 ): S35–S46.
    Direct Link:
  • 23
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463–472.
  • 24
    Casiraghi MA, De Paschale M, Romano L, Biffi R, Assi A, Binelli G, et al. Long term outcomes (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. HEPATOLOGY 2004; 39: 90–96.
    Direct Link:
  • 25
    Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167: 743–750.
  • 26
    Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000; 181: 35–41.
  • 27
    Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938–945.
  • 28
    Buti M, San Miguel R, Brosa M, Cabasés JM, Medina M, Angel Casado M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639–645.
  • 29
    McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 2005; 11: S286–S295.
  • 30
    Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody–positive subjects in a community-based cohort study. HEPATOLOGY 2009; doi:10.1002/hep.23002.
    Direct Link:
View Full Article with Supporting Information (HTML) Get PDF (58K)